Nativa, tablets 0.2 mg 30 pcs

Nativa has antidiuretic effect, stimulates the activity of clotting factor VIII. It increases permeability of epithelium of distal sections of convoluted tubules for water and increases its reabsorption. Antidiuretic effect develops with parenteral routes of administration (p/u, i/m, i/v) and instillation into the nose.

While the T1/2 is 75 min, it persists for 8-20 h. Daily and nocturnal polyuria disappears after 2-3 doses, and IV administration is 10 times more effective than intranasal administration.

Increases activity of coagulation factor VIII in patients with hemophilia and Willebrand’s disease: after infusion of 0.4 µg/kg its level is 300-400% of the initial level; the response is seen after 30 minutes and reaches its maximum (3-4-fold increase) within 1.5-2 hours. Factor VIII antigen activity and ristocetin-Co-factor activity increase to a lesser extent.

Desmopressin equally increases the content of factor VIII in mild hemophilia A, Willebrand disease and in healthy volunteers. There is also a rapid increase in plasminogen concentration without a clinically significant increase in fibrinolysis.

Indications

Nonspecific diabetes, acute polyuria, polydipsia after pituitary surgery, primary nocturnal urinary incontinence (for intranasal use only).

Active ingredient

Composition

Active ingredient:

desmopressin acetate 0.2 mg;

Associates:

Lactose monohydrate, 10/10 mg;

crospovidone XL, 5/5 mg;

Magnesium stearate, 2/2 mg;

ludipress – up to 200/up to 200 mg (lactose monohydrate – 170.1/170 mg; crosspovidone – 6.4/6.4 mg; povidone – 6.4/6.4 mg)

How to take, the dosage

Ingestion. The optimal dose of the drug is chosen individually.

The drug should be taken some time after meals because eating may affect absorption of the drug and its effectiveness.

Central non-sugar diabetes: The recommended starting dose for children over 4 years of age and adults is 0.1 mg 1-3 times daily. Thereafter, the dose is adjusted depending on the response to treatment.

The usual daily dose is 0.2 to 1.2 mg. For most patients, the optimal maintenance dose is 0.1 to 0.2 mg 1 to 3 times a day.

Primary nocturnal enuresis: The recommended starting dose for children over 5 years of age and adults is 0.2 mg at night. If there is no effect, the dose may be increased to 0.4 mg. The recommended course of continuous treatment is 3 months.

The decision to continue treatment should be made on the basis of clinical data, which will be observed after discontinuation of the drug for 1 week. Compliance with evening fluid restriction should be monitored.

Nighttime polyuria in adults: The recommended starting dose is 0.1 mg at night. If there is no effect within 7 days, the dose is increased to 0.2 mg and subsequently to 0.4 mg (frequency of dose increase is not more than once a week). It is necessary to remember about the danger of fluid retention in the body.

If after 4 weeks of treatment and dose adjustment there is no adequate clinical effect, continuation of the drug is not recommended.

Contraindications

Hypersensitivity, congenital or psychogenic polydipsia, anuria, fluid retention of various etiologies, hypo-osmolarity of plasma, circulatory insufficiency, need for diuretic therapy.

Similarities